Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33047
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe Castella A.R.en
dc.contributor.authorBurger H.en
dc.contributor.authorRiedel A.en
dc.contributor.authorRolfe T.J.en
dc.contributor.authorFitzgerald P.B.en
dc.contributor.authorTaffe J.en
dc.contributor.authorKulkarni J.en
dc.date.accessioned2021-05-14T11:12:18Zen
dc.date.available2021-05-14T11:12:18Zen
dc.date.copyright2002en
dc.date.created20021212en
dc.date.issued2012-10-18en
dc.identifier.citationArchives of Women's Mental Health. 5 (3) (pp 99-104), 2002. Date of Publication: November 2002.en
dc.identifier.issn1434-1816en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/33047en
dc.description.abstractA double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 mug transdermal estradiol or b) 100 mug transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 mug of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 mug estradiol or placebo groups. The addition of 100 mug adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.en
dc.languageenen
dc.languageEnglishen
dc.publisherSpringer Wien (Sachsenplatz 4-6, P.O. Box 89, Vienna A-1201, Austria)en
dc.titleA clinical trial of adjunctive oestrogen treatment in women with schizophrenia.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1007/s00737-002-0001-5en
dc.publisher.placeAustriaen
dc.identifier.pubmedid12510212 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12510212]en
dc.identifier.source35387787en
dc.identifier.institution(Kulkarni, Riedel, De Castella, Fitzgerald, Rolfe) Dandenong Psychiat. Research Centre, Monash University, Dept. of Psychological Medicine, Melbourne, Vic., Australia (Taffe) School of Mathematical Sciences, Swinburne University, Melbourne, Vic., Australia (Burger) Prince Henry's Inst. of Med. Res., Monash Medical Centre, Clayton, Vic., Australia (Kulkarni) Alfred Psychiatry Research Centre, Alfred Hospital, Commercial Road, Prahran, Vic. 3181, Australiaen
dc.description.addressJ. Kulkarni, Alfred Psychiatry Research Centre, Alfred Hospital, Commercial Road, Prahran, Vic. 3181, Australia. E-mail: jayashri.kulkarni@med.monash.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsDopamine Oestrogen/estrogen Prolactin Schizophrenia Serotoninen
dc.identifier.authoremailKulkarni J.; jayashri.kulkarni@med.monash.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptMental Health-
Appears in Collections:Articles
Show simple item record

Page view(s)

26
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.